Pharmafile Logo
Pharmafocus logo
Advanced Search

Cancer

Showing 15 posts of 1067 posts found.

FDA approves BMS’ multiple myeloma combo after it doubles progression-free survival

November 7, 2018
Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, Empliciti, FDA, US, multiple myeloma, pharma

The FDA has seen fit to approve Bristol-Myers Squibb’s Empliciti (elotuzumab) intravenous injection in combination with pomalidomide and dexamethasone for …

News
merckincweb2

MSD’s Keytruda/chemo combo scores first-line FDA approval in NSC lung cancer

November 1, 2018
Sales and Marketing Cancer, MSD, NSCLC, keytruda, lung cancer, pharma

MSD’s blockbuster anti-PD-1 immunotherapy has secured another FDA approval, it has emerged, in combination with carboplatin and either paclitaxel or …

News

NICE turns down Sanofi’s Caprelsa for rare thyroid cancer

October 31, 2018
Research and Development, Sales and Marketing Cancer, Caprelsa, NHS, NICE, Sanofi, UK, medullary thyroid cancer, pharma

NICE has announced its recommendation to reject Sanofi’s Caprelsa (vandetanib) for use on the NHS in the treatment of medullary …

News

Half of kidney cancer patients initially misdiagnosed

October 30, 2018
Manufacturing and Production Cancer, Kidney cancer, NHS, UK, diagnosis

Half of kidney cancer patients are initially misdiagnosed, according to data from Kidney Cancer UK’s patient survey. Despite being the …

News
acute_lymphoblastic_leukaemia_smear

New $2 million programme aims at increasing diversity in cancer research

October 24, 2018
Research and Development Cancer, USA, black, cancer research, diversity, latino, native american

The National Cancer Institute are developing a joint cancer drug discovery and development, and research education programme focused towards the …

News
roche

Roche’s Alecensa topples Pfizer’s Xalkori in Asian patients with ALK+ advanced lung cancer

October 23, 2018
Manufacturing and Production, Research and Development Alecensa, Cancer, ESMO 2018, Roche, lung cancer, pharma

Following up on the reveal of data concerning its immunotherapy Tecentriq in combination with chemotherapy in the treatment of non-small …

News
merckincweb2

First-line Keytruda shows better overall survival in head & neck cancer

October 23, 2018
Manufacturing and Production, Research and Development Cancer, ESMO 2018, MSD, head and neck cancer, keytruda, pharma

MSD’s Keytruda (pembrolizumab) made an impact at the European Society for Medical Oncology 2018 Congress as the company unveiled new …

News
image_credit_-_rafael_matsunaga

Shares in Mirati plummet after disappointing Phase II trial

October 23, 2018
Manufacturing and Production Cancer, Mirati, leuakemia, plummet, stocks

Shares in the California-based biotech Mirati Therapuetics plummeted on Monday after the company released disappointing results from their Phase II …

News
roche_dark_0

Roche’s Tecentriq+chemo boosts survival in first-line non-small cell lung cancer

October 22, 2018
Research and Development, Sales and Marketing Cancer, Roche, lung cancer NSCLC, pharma, tecentriq

Roche joined other major players like Bristol-Myers Squibb in revealing strong data on their cancer immunotherapies at the European Society …

News

BMS’ Opdivo and Yervoy combination shows outstanding survival rate in cancer patients

October 22, 2018
Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, Yervoy, melanoma, opdivo

American pharma firm Bristol-Myers Squibb have announced that more than 53% of patients with advanced melanoma, who were treated with …

News
merckincweb

MSD’s Keytruda with Pfizer’s Inlyta beats Sutent in most common kidney cancer

October 19, 2018
Medical Communications, Research and Development Cancer, Kidney cancer, MSD, Pfizer, inlyta, keytruda, pharma

MSD has unveiled new Phase 3 data on its blockbuster anti-PD-1 cancer therapy Keytruda (pembrolizumab) as part of a combination, …

News
novartis_window

Novartis snaps up cancer drug developer Endocyte for $2.1 billion

October 18, 2018
Research and Development, Sales and Marketing Cancer, Endocyte, Novartis, pharma

Novartis will shell out $2.1 billion to acquire cancer drug developer Endocyte in a move to leverage the company’s technology …

News

FDA approves Pfizer’s Talzenna for breast cancer alongside tool to identify eligible patients

October 17, 2018
Research and Development, Sales and Marketing Cancer, FDA, Pfizer, Talzenna, breast cancer, pharma

Pfizer’s Talzenna (talazoparib) has secured FDA approval, it has emerged. The poly (ADP-ribose) polymerase (PARP) inhibitor is now set to …

News
roche

Roche’s Kadcyla beats Herceptin breast cancer disease recurrence and death risk

October 16, 2018
Manufacturing and Production, Sales and Marketing Cancer, Kadcyla, Roche, breast cancer, pharma

Roche has unveiled new data for its antibody-drug conjugate Kadcyla (trastuzumab emtansine) in the treatment of patients with HER2-positive early …

News

BMS’ Opdivo fails to improve overall survival in small-cell lung cancer

October 15, 2018
Research and Development, Sales and Marketing BMS< Opdivo, Bristol-Myers Squibb, Cancer, lung cancer, pharma

Bristol-Myers Squibb’s Opdivo (nivolumab) failed to deliver on its primary endpoint in a Phase 3 study in small-cell lung cancer, …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026